---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012264"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:58:21.992497+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M

## Summary
- Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).
- GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).
- 2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.
- Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.
- Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025.

## SEC filing metadata
- accession: 0001628280-26-012264
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/0001628280-26-012264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfs-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012264
- JSON: https://secwatch.observer/filing/0001628280-26-012264.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.